A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of budesonide (using Symbicort which is budesonide and
formoterol) and fluticasone (using Advair which is fluticasone and salmeterol) on the airway
microorganisms of patients with moderate-to-severe chronic obstructive pulmonary disease
(COPD). This is a randomized, parallel group, two-centered clinical trial study to evaluate
the effects of a 12 week treatment with Symbicort 400 mcg BID and Advair 250 mcg BID (via
Diskus) on airway microbiota in patients with moderate-to-severe COPD. The control arm of
this study will be Oxeze 12 ug BID.
Phase:
Phase 2
Details
Lead Sponsor:
University of British Columbia
Collaborator:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Formoterol Fumarate